Overview of the BOSTON Trial Evaluating a Selinexor Triplet Regimen
Noa Biran, MD, discusses how the phase III BOSTON trial evaluates selinexor + bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed/refractory myeloma.
EP: 1.Addressing Unmet Needs in Relapsed/Refractory Multiple Myeloma
EP: 2.Breakthrough Agents Reshaping RRMM Treatment Landscape
Now Viewing
EP: 3.Overview of the BOSTON Trial Evaluating a Selinexor Triplet Regimen
EP: 4.Examining Selinexor Role in RRMM Treatment
EP: 5.STOMP Study: Effective Selinexor Regimen in Multitherapy Combo
EP: 6.Sequencing Selinexor With Novel BCMA Therapies
EP: 7.Multiple Myeloma: Evolving Therapies and Patient Well-Being
EP: 8.Optimizing Novel Treatment Options in Relapsed/Refractory Multiple Myeloma
Related Videos
